AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18578170 — intervention group
Group type: EXPERIMENTAL
Intervention: 22% carbamide peroxide solution (Nite White Excel 3)
Number of subjects: 96
Study 18578170 — intervention group
Group type: COMPARATOR
Intervention: Tap water (control)
Number of subjects: 96
Study 18578170 — intervention group
Group type: EXPERIMENTAL
Intervention: Reservoirs in custom trays
Number of subjects: 96
Study 16055224 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix-in-cylinder system (80 mg propranolol hydrochloride)
Number of subjects: 10
Study 16055224 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix-in-cylinder system (80 mg propranolol hydrochloride) under fed conditions
Number of subjects: 10
Study 16055224 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix-in-cylinder system (80 mg propranolol hydrochloride) under fasted conditions
Number of subjects: 10
Study 16055224 — intervention group
Group type: COMPARATOR
Intervention: Inderal (commercial pellet formulation)
Number of subjects: 10
Study 11943418 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 215
Study 11943418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 10356104 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin alone or in combination with low doses of warfarin
Number of subjects: 2012
Study 10356104 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 2012
Study 10356104 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular consumption of >/=14 alcohol-containing drinks per week
Number of subjects: 2012
Study 10356104 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen hormone replacement therapy among SPAF III participants
Number of subjects: 2012
Study 10356104 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification scheme based on identified factors
Number of subjects: 2012
Study 10356104 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk participants
Number of subjects: 2012
Study 7489455 — intervention group
Group type: EXPERIMENTAL
Intervention: Sniff Position Pillow (SPP)
Number of subjects: 21
Study 7489455 — intervention group
Group type: COMPARATOR
Intervention: Shoulder Elevation (SE)
Number of subjects: 21
Study 1954814 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual insulin (isoglycemic study)
Number of subjects: 20
Study 1954814 — intervention group
Group type: EXPERIMENTAL
Intervention: Omitting morning short‐acting insulin (hyperglycemic study)
Number of subjects: 20
Study 1954814 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic subjects
Number of subjects: 20
Study 6328390 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 0
Study 6328390 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin (ticarcillin or cloxacillin) and gentamicin
Number of subjects: 0
Study 6328390 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 0
Study 30733088 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider communication intervention
Number of subjects: 777
Study 30733088 — intervention group
Group type: EXPERIMENTAL
Intervention: Very strong recommendation
Number of subjects: 777
Study 30733088 — intervention group
Group type: EXPERIMENTAL
Intervention: Presumptive recommendation
Number of subjects: 777
Study 30733088 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 777
Study 29562932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 0
Study 29562932 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET)
Number of subjects: 0
Study 29562932 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29562932 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary measures
Number of subjects: 0
Study 27765365 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligopin (OP) 75 mg, 2 capsules/day for 5 weeks
Number of subjects: 24
Study 27765365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 24997315 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 1651
Study 24997315 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 1651
Study 24997315 — intervention group
Group type: EXPERIMENTAL
Intervention: Both metronidazole and clarithromycin
Number of subjects: 1651
Study 24997315 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior unsuccessful eradication treatments
Number of subjects: 1651
Study 24997315 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 1651
Study 24997315 — intervention group
Group type: EXPERIMENTAL
Intervention: Country or continent of origin
Number of subjects: 1651
Study 22994843 — intervention group
Group type: EXPERIMENTAL
Intervention: DELFIN parenting program
Number of subjects: 65
Study 22994843 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study 20402873 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope Video Laryngoscope
Number of subjects: 18
Study 20402873 — intervention group
Group type: COMPARATOR
Intervention: Direct Laryngoscopy
Number of subjects: 18
Study 22117707 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted bone drilling method (test group)
Number of subjects: 29
Study 22117707 — intervention group
Group type: COMPARATOR
Intervention: Standard drilling protocol (control group)
Number of subjects: 29
Study 16210486 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV), two doses in a 4- to 6-week interval, followed by a booster dose of 23-valent polysaccharide vaccine (PPV) after one year
Number of subjects: 33
Study 16210486 — intervention group
Group type: COMPARATOR
Intervention: 23-valent polysaccharide vaccine (PPV), two doses in a 1-year interval
Number of subjects: 33
Study 16210486 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV priming
Number of subjects: 33
Study 12227126 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-osteoporosis interventions
Number of subjects: 0
Study 12227126 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in bone density
Number of subjects: 0
Study 9868644 — intervention group
Group type: EXPERIMENTAL
Intervention: 400‐mg once‐weekly fluconazole
Number of subjects: 636
Study 9868644 — intervention group
Group type: COMPARATOR
Intervention: 200‐mg daily fluconazole
Number of subjects: 636
Study 7993990 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg pyrantel pamoate tablet formulation
Number of subjects: 9
Study 7993990 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg pyrantel pamoate suspension formulation
Number of subjects: 9
Study 7993990 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg pyrantel pamoate other formulation
Number of subjects: 9
Study 7993990 — intervention group
Group type: COMPARATOR
Intervention: All formulations
Number of subjects: 9
Study 7993990 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 9
Study 3197751 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketanserin 40 mg b.d. for two months
Number of subjects: 14
Study 3197751 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketanserin treatment
Number of subjects: 14
Study 3197751 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 14
Study 31250938 — intervention group
Group type: EXPERIMENTAL
Intervention: DOMUS intervention (accelerated transition from oncological to specialist palliative care)
Number of subjects: 38
Study 31250938 — intervention group
Group type: EXPERIMENTAL
Intervention: DOMUS intervention
Number of subjects: 38
Study 30407361 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual biofeedback balance training
Number of subjects: 56
Study 30407361 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral wedge insoles (5°)
Number of subjects: 56
Study 30407361 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual rehabilitation program)
Number of subjects: 56
Study 26772624 — intervention group
Group type: EXPERIMENTAL
Intervention: NHCPlus
Number of subjects: 229
Study 26772624 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 229
Study 25563311 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD plus oral MONT (10 μg, qn) for 4 weeks
Number of subjects: 65
Study 25563311 — intervention group
Group type: COMPARATOR
Intervention: Inhaled BUD (200 μg, bid) for 4 weeks
Number of subjects: 65
Study 23499539 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 40
Study 23499539 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory muscle training
Number of subjects: 40
Study 23499539 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined inspiratory and expiratory muscle training
Number of subjects: 40
Study 23499539 — intervention group
Group type: COMPARATOR
Intervention: Control group (lower limb muscle exercise only)
Number of subjects: 40
Study 20856190 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors (specific dosage and duration not mentioned)
Number of subjects: 16
Study 20856190 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain perfusion [(99m)Tc]ECD / SPECT and structural MRI
Number of subjects: 16
Study 17976988 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 1250 mg/m² orally bid days 1-14
Number of subjects: 47
Study 17976988 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine 30 mg/m² i.v. days 1 and 8
Number of subjects: 47
Study 15703953 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan (HA) alone
Number of subjects: 40
Study 15703953 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan (HA) with corticosteroid (triamcinolone acetonide)
Number of subjects: 40
Study 15703953 — intervention group
Group type: COMPARATOR
Intervention: Control group (HA alone)
Number of subjects: 40
Study 15703953 — intervention group
Group type: COMPARATOR
Intervention: Control group (HA with corticosteroid)
Number of subjects: 40
Study 12510181 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical acupuncture therapy via adhesive surface electrodes and auricular acupuncture therapy
Number of subjects: 100
Study 12510181 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation therapy
Number of subjects: 100
Study 10824627 — intervention group
Group type: EXPERIMENTAL
Intervention: TS-943
Number of subjects: 36
Study 8944408 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine 100 mg
Number of subjects: 0
Study 8944408 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 0
Study 8944408 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg
Number of subjects: 0
Study 8944408 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 0.5 mg
Number of subjects: 0
Study 8944408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1629823 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose intravenous methotrexate (MTX) (500 mg/m2) followed by oral leucovorin every 2 weeks for up to 6 months
Number of subjects: 8
Study 1629823 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose MTX after the high dose protocol
Number of subjects: 8
Study 1629823 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8
Study 6748672 — intervention group
Group type: EXPERIMENTAL
Intervention: Distilled spirits
Number of subjects: 64
Study 6748672 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer
Number of subjects: 64
Study 6748672 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corresponding to distilled spirits)
Number of subjects: 64
Study 6748672 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corresponding to beer)
Number of subjects: 64
Study 30217604 — intervention group
Group type: COMPARATOR
Intervention: Lateral tarsal strip alone with non-invasive stenting of the punctum
Number of subjects: 40
Study 30217604 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral tarsal strip with three-snip punctoplasty
Number of subjects: 40
Study 26663908 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight prevalence based on CDC criteria
Number of subjects: 6574
Study 26663908 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight prevalence based on IOTF criteria
Number of subjects: 6574
Study 26663908 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight prevalence based on WHO criteria
Number of subjects: 6574
Study 26663908 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity prevalence based on CDC criteria
Number of subjects: 6574
Study 26663908 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity prevalence based on IOTF criteria
Number of subjects: 6574
Study 26663908 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity prevalence based on WHO criteria
Number of subjects: 6574
Study 24598599 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain diet
Number of subjects: 61
Study 24598599 — intervention group
Group type: COMPARATOR
Intervention: Refined cereal diet (control)
Number of subjects: 61
Study 21985079 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast track care
Number of subjects: 400
Study 20477825 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar transurethral resection in saline (TURIS)
Number of subjects: 100
Study 20477825 — intervention group
Group type: COMPARATOR
Intervention: Monopolar transurethral resection of the prostate (TURP)
Number of subjects: 100
Study 17545068 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Stroop task
Number of subjects: 13
Study 15675977 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol changed to desflurane
Number of subjects: 42
Study 15675977 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane changed to desflurane
Number of subjects: 42
Study 11908712 — intervention group
Group type: EXPERIMENTAL
Intervention: ACOP+ (cyclophosphamide, doxorubicin, vincristine, 6-mercaptopurine, and prednisone)
Number of subjects: 120
Study 11908712 — intervention group
Group type: COMPARATOR
Intervention: APO (doxorubicin, vincristine, 6-mercaptopurine, and prednisone)
Number of subjects: 120
Study 9793671 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium, 0.20 mg.kg‐1 (4 x ED95)
Number of subjects: 100
Study 9793671 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium, 0.30 mg.kg‐1 (6 x ED95)
Number of subjects: 100
Study 9793671 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium, 0.30 mg.kg‐1 (6 x ED95)
Number of subjects: 100
Study 9793671 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium, 0.40 mg.kg‐1 (8 x ED95)
Number of subjects: 100
Study 7541158 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin plus paclitaxel
Number of subjects: 0
Study 7541158 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus paclitaxel
Number of subjects: 0
Study 7541158 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin
Number of subjects: 0
Study 7541158 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 0
Study 2565210 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg twice daily)
Number of subjects: 8
Study 2565210 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (5 mg daily)
Number of subjects: 8
Study 336056 — intervention group
Group type: EXPERIMENTAL
Intervention: NAB 365 (clenbuterol-HCl) 24 micrograms, 3 times daily for 7 days
Number of subjects: 30
Study 336056 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol HBr 5 mg, 3 times daily for 7 days
Number of subjects: 30
Study 29748736 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended 24-week Social Skills Group Training (SSGT) program KONTAKT
Number of subjects: 50
Study 29748736 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 50
Study 27631775 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (SC) - 5×5 Gy in 1 week, early surgery, and 6 courses of adjuvant chemotherapy.
Number of subjects: 0
Study 27631775 — intervention group
Group type: COMPARATOR
Intervention: Long-course chemoradiotherapy (LC) - 50.4 Gy in 28 fractions over 5.5 weeks with infusion of 5-fluorouracil, surgery in 4 to 6 weeks, and 4 courses of chemotherapy.
Number of subjects: 0
Study 27631775 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (SC)
Number of subjects: 0
Study 27631775 — intervention group
Group type: COMPARATOR
Intervention: Long-course chemoradiotherapy (LC)
Number of subjects: 0
Study 26437027 — intervention group
Group type: COMPARATOR
Intervention: Magnetic sphincter augmentation device (MSAD)
Number of subjects: 44
Study 23712056 — intervention group
Group type: EXPERIMENTAL
Intervention: Test of Infant Motor Performance (TIMP)
Number of subjects: 95
Study 23712056 — intervention group
Group type: EXPERIMENTAL
Intervention: Alberta Infant Motor Scale (AIMS)
Number of subjects: 95
Study 23712056 — intervention group
Group type: EXPERIMENTAL
Intervention: AIMS at 6 months CA
Number of subjects: 95
Study 23712056 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental-reported walking age
Number of subjects: 95
Study 21220339 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 0
Study 21220339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19762662 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-prevention group intervention
Number of subjects: 1047
Study 19762662 — intervention group
Group type: COMPARATOR
Intervention: Individual-care and attention-matched controls
Number of subjects: 1047
Study 17563166 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking moderation training with intervention enhancements (life skills training and booster sessions)
Number of subjects: 144
Study 17563166 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking moderation training
Number of subjects: 144
Study 15459218 — intervention group
Group type: EXPERIMENTAL
Intervention: PRT + TME
Number of subjects: 96
Study 15459218 — intervention group
Group type: COMPARATOR
Intervention: TME alone
Number of subjects: 96
Study 11437028 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 60 microg PGE1 over 2 hours during pedalergometry
Number of subjects: 10
Study 11437028 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (similar training program without PGE1)
Number of subjects: 10
Study 9557427 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine (25 mg/day) and Pyridoxine (50 mg/day)
Number of subjects: 200
Study 9557427 — intervention group
Group type: COMPARATOR
Intervention: Thiamine (1 mg/day) and Pyridoxine (1 mg/day)
Number of subjects: 200
Study 8345047 — intervention group
Group type: EXPERIMENTAL
Intervention: Nal-Glu plus T (100 micrograms/kg.day sc plus T enanthate, 200 mg im weekly)
Number of subjects: 19
Study 8345047 — intervention group
Group type: COMPARATOR
Intervention: T alone (placebo sc injections daily plus T enanthate, 200 mg im weekly)
Number of subjects: 19
Study 8345047 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Nal-Glu plus T and T alone)
Number of subjects: 19
Study 3725517 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly booster sessions after training
Number of subjects: 28
Study 3725517 — intervention group
Group type: COMPARATOR
Intervention: No booster sessions after training
Number of subjects: 28
Study 30476007 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined behavioral and biomedical intervention
Number of subjects: 46
Study 30476007 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral of sexual partners by passive referral
Number of subjects: 46
Study 30476007 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylogenetic analysis of index-partner pairs
Number of subjects: 46
Study 30476007 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic analysis of dyads
Number of subjects: 46
Study 30476007 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral analysis of index participants
Number of subjects: 46
Study 30322392 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calorie diet (LCD)
Number of subjects: 97
Study 30322392 — intervention group
Group type: COMPARATOR
Intervention: Weight maintenance diet (control)
Number of subjects: 97
Study 27010809 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg loading dose before PPCI, followed by 90 mg twice daily for 1 year)
Number of subjects: 400
Study 27010809 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (600 mg loading dose before PPCI, followed by 75 mg once daily for 1 year)
Number of subjects: 400
Study 24993911 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention (additional visits, telephone calls, education)
Number of subjects: 3100
Study 24993911 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention (usual follow-up care)
Number of subjects: 3100
Study 22732382 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium cream 4%
Number of subjects: 60
Study 22732382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19932545 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise training
Number of subjects: 70
Study 19932545 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise training
Number of subjects: 70
Study 19932545 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study 17368650 — intervention group
Group type: EXPERIMENTAL
Intervention: Single circuit-resistance training (10 exercises at 35% of 1RM)
Number of subjects: 20
Study 15922820 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine oral solution (2.5 mg/kg or 5 mg/kg BID)
Number of subjects: 210
Study 15922820 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine extemporaneous solution (2.5 mg/kg or 5 mg/kg BID)
Number of subjects: 210
Study 15922820 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine capsules (150 mg BID for ages 13-18)
Number of subjects: 210
Study 15922820 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine (all formulations)
Number of subjects: 210
Study 12876092 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant results (P<=0.05)
Number of subjects: 510
Study 12876092 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsignificant results (P>0.05 or not reported)
Number of subjects: 510
Study 12876092 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral or plenary presentation
Number of subjects: 510
Study 12876092 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical sponsorship
Number of subjects: 510